In 1968, Bauer (of the Kirby-Bauer test) wrote, "No information concerning the quantity or quality of laboratory examinations in physicians' offices and clinics is available; however, . . . this is where a large percentage of laboratory testing is done."
1 Unfortunately, as of 2017, this statement is largely still true for laboratories in much of sub-Saharan Africa (SSA). With a few exceptions, [2] [3] [4] previous studies of SSA clinical laboratories have been descriptive, based on single tests, 5 or focused on a few target laboratories. 6, 7 Little is known about the accuracy and costs of tests in laboratories that perform the bulk of diagnostic testing in SSA. To obtain this information, we tested a panel of blinded samples in 78 randomly selected laboratories in Kampala, Uganda.
Our first survey of laboratories in Kampala was a comprehensive cross-sectional survey performed in late 2011. That survey identified almost 1,000 laboratories doing over 13,000 tests daily. 4 Only 5% of identified laboratories met the lowest standards of the laboratory quality checklist created by the World Health Organization (WHO) African regional office, 4, 8 and the prices of the most common tests ranged from $1.83 to $3.46. The survey also showed that laboratories in Kampala are generally of two varieties: small laboratories doing simple point-of-care (POC) kit or light microscope testing, and larger laboratories doing more complex testing. 9 However, the 2011 survey had two shortcomings. First, costs were based on prices listed on laboratory menus and not on actual charges to the laboratory's customers. Second, although the best way to objectively assess laboratory test accuracy is to use blinded samples, measures of quality were based on compliance with a WHO checklist Am and not on the accuracy of actual tests performed by the laboratories. 4, 10 The use of split blinded samples, known as proficiency testing (PT), is the most common measure of accuracy in laboratories worldwide. This system of checking laboratory accuracy started in the 1950s 11, 12 and continues today in countries around the world. The frequency with which these samples are sent and the passing criteria vary by country and PT provider. But in general, each laboratory enrolled in PT programs receives three or more PT challenges for each test every year. The Royal College of Pathologists of Australasia's Quality Assurance Programs (RCPAQAP) is one of the largest suppliers of PT in the world. It supplies PT material to laboratories in over 60 countries. To directly measure test accuracy and cost, as well as provide a practical method for future studies, we tested blinded RCPAQAP samples in 78 randomly selected laboratories in Kampala, Uganda. The tests were paid for at market rates.
Materials and Methods

Study Design
A total of 40 moderate-to high-complexity laboratories and 38 low-complexity laboratories were randomly selected from a comprehensive list of all laboratories in Kampala, Uganda. 4 As previously described, laboratories that performed only simple kit tests or light microscope examinations were considered low complexity. 9 Our previous survey had demonstrated that 95% of the laboratories in Kampala were private and that only 0.3% met international quality standards. 4 To match these proportions, 73 (94%) of these 78 randomly selected laboratories were private, and one met international quality standards. Two other internationally accredited laboratories were selected to serve as references for locally sourced PT material and to account for matrix effects or potential deterioration of the externally sourced PT materials.
Moderate-to High-Complexity Laboratories
Forty-two moderate-to high-complexity laboratories (40 random plus two accredited) were selected from the list of laboratories identified in the 2013 survey. They were sent samples and paid at market rates to perform 13 of the most commonly used tests in Kampala Each of the medium-to high-complexity laboratories received two sets of samples delivered over a 36-hour window by one of three trained couriers. Samples were stored at 4°C while awaiting pickup by the couriers. Each courier was assigned specific, nonoverlapping geographic regions throughout the city, along with a list of randomized, previously documented moderateto high-complexity laboratories within that area. They were also trained in how to safely transport these biological samples, as well as provided with reimbursement for the laboratory tests and for transportation via "boda boda"-motorbike taxis. All laboratories surveyed provided receipts and either a printed or handwritten result report. Less than two-thirds (62.5%) of all laboratories sampled were able to provide all laboratory tests requested. The general rule was to proceed with testing only if more than nine of the 13 individual tests were available. The two sets of laboratory samples (CL-16-1001 and CL-16-1002), along with their respective values, are listed in ❚Table 1❚.
Low-Complexity Laboratories
We generated a random list of low-complexity laboratories from those identified in the earlier survey. 4 The city was divided into three geographic regions, and the three couriers were again each given a randomized list of low-complexity laboratories to visit in their respective regions. Unfortunately, many of these laboratories had closed or moved in the 5 years between the 2011 original survey and the commencement of this study. After exhausting their lists, couriers were encouraged to select other low-complexity laboratories, of which there were many to choose from. Only laboratories that did not perform automated CBCs or standard chemistries were used in this portion of the study.
A total of 38 laboratories were selected, and four qualitative laboratory tests-HIV screen, malaria blood smear, urine hCG, and syphilis screen-were ordered and paid for at each laboratory. Three separate sets of laboratory samples were prepared for this population of low-complexity laboratories. The samples 
Sample Preparation
Samples for serum chemistries (glucose, serum urea nitrogen, Cr, AST, ALT), as well as positive hCG samples, were provided by the RCPAQAP. Hematology, HIV, syphilis, and malarial samples were obtained locally. Briefly, two whole-blood samples were provided by two healthy DOI: 10.1093/ajcp/aqy017 © American Society for Clinical Pathology volunteers, with the second sample being diluted 1:1 serum-to-whole blood to mimic anemia. HIV-and syphilis-positive serum samples slated for discard were deidentified and collected over the course of several weeks from the core laboratory at the Infectious Disease Institute in Kampala. HIV-and syphilis-negative serum was collected from seronegative volunteers. No positive malaria smears were available during the limited sample-accruing window, so we were unable to test for the rate of false negativity. However, we were able to test the possibility of false-positive results. Testing for false-positive results was considered the driver to still have malaria PT for this study. Some laboratories had rapid malarial tests available, but the majority used microscopy for malarial identification.
Data Analysis
Acceptable results for glucose, serum urea nitrogen, Cr, AST, and ALT were based on targets and acceptable ranges as defined by the RCPAQAP. Acceptable results for WBC, hemoglobin, hematocrit, and platelets were based on means and standard deviations established using repeated measurements from the two accredited laboratories. Acceptable results for the qualitative tests were based on the known positive and negative samples used to constitute the sample sets. Linear regression was used to examine the relationship between the overall pass rates and test costs.
Results
Overall Test Cost and Accuracy
❚Table 3❚ shows the average test cost and accuracy for the 13 analytes that were tested in this survey of laboratory accuracy in Kampala. Pass rates by test type were 96% for malarial blood smear, 95% for HIV, 91% for syphilis, 88% for platelet count, 83% for hCG, 80% for WBCs, 78% for AST, 78% for hemoglobin, 77% for Cr, 61% for ALT, 53% for hematocrit, 42% for glucose, and 38% for serum urea nitrogen. The overall pass rate was 77.1%. Quantitative and qualitative pass rates were 66% (range, 31%-89%) and 91% (range, 68%-97%) respectively. PT scores of the three internationally certified laboratories were 100%, 100%, and 92%, respectively. For most analytes, the laboratory pass rates were similar for both challenge samples (data not shown). However, this was not the case for hCG, where the accuracy for CL- 16 Test costs for the 13 analytes tested (Table 3) were also quite variable. For example, costs for malaria blood smears ranged from syphilis $0.29 to $10.59.
Performance of Chemistry and Hematology Analytes
Test Accuracy of Quantitative Tests
❚Figure 1❚ shows histograms detailing the laboratory performance for chemistry and hematology analytes. The solid black bars represent those laboratory results that were within the acceptable range, defined based on RCPAQAP criteria or as within three standard deviations above and below the mean. The percentage of laboratories meeting target values for each analyte varied from a low of 45% for glucose to a high of 82% for AST. For each analyte, at least 6% of results were egregiously inaccurate: greater than nine standard deviations from the mean and often double or half the target value. Such values were not uncommon, particularly for glucose and serum urea nitrogen. 
Discussion
Our study of laboratory test cost and accuracy in Kampala, Uganda, has three key findings. First, test costs varied by up to 3,600% for individual tests across laboratories in Kampala. This wide variance in laboratory test costs is not unique to SSA, but its impact is uniquely felt in SSA. For example, a 2011 study of the charges for 10 common blood tests in 166 California hospitals showed up to a 1,000-fold difference in the costs of individual tests, 13 yet since 66% of patients were either on Medicare or Medicaid, the actual costs were largely based on the payer (clinical laboratory fee schedule of the federal government) rather than the seller (hospital laboratories). This payer-set rate is much lower than the median hospital charge and tends to be more consistent across institutions. In contrast, private laboratories in Kampala are pure fee-for-service establishments, with minimal price adjustments due to government programs and foreign aid. This begs the following question: why would a consumer choose to pay over 3,600% more for a given test rather than comparison shop for more favorable prices? Or, given that price is not the only driver of clinical laboratory utilization, should global efforts to increase access to clinical laboratory testing, which rely heavily on economic analysis and allocation of resources, also include market forces as opposed to solely focusing on the cost to provide the services? Our findings imply that a single-minded focus on cost is inadequate because price is not the only driver of demand.
14 A perceived difference in quality can drive demand just as effectively as a difference in price. [14] [15] [16] This "you get what you pay for" idea makes it easier for customers to make what feel like rational choices in the poorly controlled and often unregulated clinical diagnostic laboratory market in SSA. 2, 3, 17 But is this perception correct? Is there a difference in quality between laboratories in Kampala?
The answer is yes, and it highlights the second key finding of this study: there were significant differences in accuracy between laboratories. Test accuracy varied by test classification (quantitative vs qualitative) as well as by test type (HIV vs serum urea nitrogen). While this inconsistency in quality is noteworthy, it is not new. Previous studies of clinical laboratory testing in SSA, whether focused on individual cities or large regions, have demonstrated that although quality is generally poor, 4, 17 there are a few high-quality laboratories available. 3, 18 For clinical laboratory customers in SSA, this creates a dilemma. They know that the quality of most laboratories is poor, and yet there is no obvious way of identifying the more reliable providers. One approach is to use test prices as a guide for identifying more reliable, higher quality laboratories. But this approach, which assumes that higher prices predict better quality, is not supported by our data.
The third key finding of our study is that there was no correlation between price and quality for clinical laboratories in Kampala. Cost was not a reliable predictor of accuracy. While it is not clear how generalizable this finding is for laboratories in other low-resource settings, the implications of this opaque marketplace are enormous. This lack of transparent quality means that even individuals with the ability and desire to pay for high-quality laboratory testing still have no real means of knowing how or where to access it. This is a disservice to clinicians who may be left with very puzzling results, to patients who pay for a potentially harmful service, and to those few laboratories that maintain high-quality standards. The answer to this problem is enhanced transparency.
For the clinical laboratory, there are two well-known ways to ensure transparent quality. The first is international accreditation. The laboratories in our survey that were accredited had an average 98% pass rate as opposed to 66% for those that were not. However, the process for seeking international accreditation is arduous and includes significant costs for highly trained personnel and other major barriers for laboratories in low-income settings. 19 The second way to ensure laboratory quality is to measure accuracy objectively using blinded samples, a system also known as external quality assurance (EQA). The first report of checking the accuracy of testing in clinical laboratories using blinded samples was by Belk and Sunderman in 1947, 11 and it quickly became a staple of quality assurance in laboratories around the world. [20] [21] [22] [23] [24] In places where EQA has been implemented broadly, there has been a positive and sustained improvement in quality. 12, 23, 25, 26 However, because EQA material is primarily produced in a handful of commercial laboratories in the West, their costs are prohibitive for laboratories in low-and middle-income countries (LMICs). 27, 28 In 2010, Elbireer et al 27 performed a 1-year study of a large nonprofit research laboratory accredited by the College of American Pathologists and located in Kampala, Uganda. Approximately 30% ($545,000) of the total direct laboratory expenses were spent on buying and performing analysis of quality control and EQA material. Consequently, most laboratories in LMICs make the financially rational choice and do not perform controls-resulting in unreliable results. The ability to produce control material locally in laboratories in SSA would decrease these costs but is rare. Our experience producing such samples locally suggests that a system for the production of control material in large clinical laboratories in SSA is feasible. Attaining the status of international accreditation in low-resource settings is an achievable 3 but challenging task. While we continue to strive for this, low-resource countries can improve quality today by widely implementing an EQA scheme using blinded samples.
Conclusions
Test cost and test accuracy varied widely across laboratories in Kampala. Test costs were not associated with quality. Our results suggest that either international accreditation or the use of blinded samples will be required to guarantee accurate results.
